Literature DB >> 16354800

Natural course of lymphatic filariasis: insights from epidemiology, experimental human infections, and clinical observations.

T V Rajan1.   

Abstract

Lymphatic filariasis has been described as a "spectral disease". Analysis of the natural course of infection in nonendemic individuals as well as experimental infections of "volunteers" suggests that the filarial parasites are not inherently aggressive infectious agents. Experimental infections of humans with infective larvae result in transient, low-level microfilaremia, if at all. Nonendemic individuals with limited exposure show no evidence of persistent infection or pathology. Nonendemic individuals exposed to repeated infections show accelerated pathology. It is tempting to speculate that normal, immunocompetent residents in an endemic area show either (a) no pathology (endemic normals) because they are subject to the relatively low levels of infection or (b) chronic pathology if they are repeatedly infected. It would appear that only those individuals rendered immunologically tolerant to filarial parasites become productively infected with the filarial parasites. The intensity of transmission may underlie the differences in clinical presentation seen in diverse global pockets of endemicity.

Entities:  

Mesh:

Year:  2005        PMID: 16354800      PMCID: PMC1405918     

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  11 in total

1.  REEVALUATION OF WORLD WAR II VETERANS WITH FILARIASIS ACQUIRED IN THE SOUTH PACIFIC.

Authors:  S C TRENT
Journal:  Am J Trop Med Hyg       Date:  1963-11       Impact factor: 2.345

2.  Microfilaraemia in Surinamese living in Amsterdam.

Authors:  R S LEEUWIN
Journal:  Trop Geogr Med       Date:  1962-12

3.  Experimental transmission of Brugia malayi and B. pahangi to man.

Authors:  J F EDESON; T WILSON; R H WHARTON; A B LAING
Journal:  Trans R Soc Trop Med Hyg       Date:  1960-05       Impact factor: 2.184

4.  Lymphatic filariasis in Madras, India.

Authors:  B Hyma; A Ramesh; K Gunasekaran
Journal:  Soc Sci Med       Date:  1989       Impact factor: 4.634

5.  Filariasis in American armed forces in World War II.

Authors:  W B WARTMAN
Journal:  Medicine (Baltimore)       Date:  1947-12       Impact factor: 1.889

Review 6.  The Wellcome Trust Lecture. Infection and disease in lymphatic filariasis: an immunological perspective.

Authors:  E A Ottesen
Journal:  Parasitology       Date:  1992       Impact factor: 3.234

7.  Evidence for protective immunity to bancroftian filariasis in the Cook Islands.

Authors:  C Steel; A Guinea; E A Ottesen
Journal:  J Infect Dis       Date:  1996-09       Impact factor: 5.226

8.  Maternal filarial infection as risk factor for infection in children.

Authors:  P J Lammie; W L Hitch; E M Walker Allen; W Hightower; M L Eberhard
Journal:  Lancet       Date:  1991-04-27       Impact factor: 79.321

9.  Observations on the clinical manifestations and treatment of an experimental infection with Brugia malayi in man.

Authors:  J Y Liu; G Q Wang; Y N Chen; Z P Tu; Z Fang
Journal:  J Trop Med Hyg       Date:  1989-04

Review 10.  Experimental infection of humans with filariae.

Authors:  T B Nutman
Journal:  Rev Infect Dis       Date:  1991 Sep-Oct
View more
  3 in total

1.  The therapeutic potential of the filarial nematode-derived immunodulator, ES-62 in inflammatory disease.

Authors:  M M Harnett; A J Melendez; W Harnett
Journal:  Clin Exp Immunol       Date:  2009-12-01       Impact factor: 4.330

Review 2.  Parasitic nematode modulation of allergic disease.

Authors:  William Harnett; Margaret M Harnett
Journal:  Curr Allergy Asthma Rep       Date:  2008-09       Impact factor: 4.806

3.  Immunoepidemiology of Wuchereria bancrofti infection: parasite transmission intensity, filaria-specific antibodies, and host immunity in two East African communities.

Authors:  Walter G Jaoko; Edwin Michael; Dan W Meyrowitsch; Benson B A Estambale; Mwele N Malecela; Paul E Simonsen
Journal:  Infect Immun       Date:  2007-10-01       Impact factor: 3.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.